Byvalson is owned by Allergan.
Byvalson contains Nebivolol Hydrochloride; Valsartan.
Byvalson has a total of 2 drug patents out of which 0 drug patents have expired.
Byvalson was authorised for market use on 03 June, 2016.
Byvalson is available in tablet;oral dosage forms.
Byvalson can be used as method of treating hypertension.
The generics of Byvalson are possible to be released after 04 October, 2027.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803838 | ALLERGAN | Compositions comprising nebivolol |
Aug, 2026
(3 years from now) | |
US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic